All In Biotech

Free tool

FAERS Monitor: Tpoxx

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 214518 or its brand name (Tpoxx, Tecovirimat). Reports on generic versions are filed under their own applications.

Reports

104

Serious

50

48% of reports

Hospitalization

23

Death reported

14

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug resistance19
  • headache14
  • nausea14
  • fatigue12
  • diarrhoea10
  • acute kidney injury6
  • alanine aminotransferase increased6
  • decreased appetite5
  • off label use5
  • abdominal pain4
  • dizziness4
  • drug ineffective4
  • skin lesion4
  • vomiting4
  • abdominal discomfort3

Reports by year received

View as table
YearReports
20203
20211
202210
202342
202435
20257
20266

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,055 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
drug resistanceSignal19149.799.72,661
skin lesionSignal429.511.384
alanine aminotransferase increasedSignal619.89.189
acute kidney injurySignal67.93.630
headacheSignal144.52.836
decreased appetiteSignal54.41.910
abdominal discomfort33.61.23
nauseaSignal143.62.224
abdominal painSignal43.51.35
diarrhoeaSignal103.11.713
fatigueSignal123.11.816
vomiting41.70.71
dizziness41.60.60
off label use51.20.50
drug ineffective40.60.21

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.